Published in Ther Adv Chronic Dis on July 01, 2012
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med (2008) 11.61
Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest (2002) 6.27
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet (2007) 3.98
Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev (2000) 3.40
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol (2007) 2.38
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 1.89
Angiotensin II receptor antagonists. Lancet (2000) 1.82
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension (2008) 1.81
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension (2006) 1.81
Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun (2003) 1.74
Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension (2002) 1.71
Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation (2009) 1.66
A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens (2007) 1.59
The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol (2002) 1.58
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet (2007) 1.57
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 1.46
Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: The ACQUIRE randomized double-blind study. J Clin Hypertens (Greenwich) (2010) 1.46
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens (2007) 1.36
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens (2007) 1.33
Oral renin inhibitors. Lancet (2006) 1.26
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension (2007) 1.16
Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia (1999) 1.14
Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care (2010) 1.14
Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J (2010) 1.10
Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) (2007) 0.98
Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens (2010) 0.98
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res (2006) 0.95
Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag (2007) 0.93
Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol (2008) 0.89
Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs (2010) 0.86
Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst (2008) 0.86
Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther (2005) 0.86
Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension (1989) 0.85
Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol (2001) 0.84
Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol (2006) 0.82
Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol (2007) 0.81
Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol (2007) 0.81
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin (2008) 0.81
Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation (1995) 0.81
Renin, prorenin and the putative (pro)renin receptor. J Renin Angiotensin Aldosterone Syst (2005) 0.80
Effects of an orally active renin inhibitor, Ro 42-5892, in patients with essential hypertension. Am J Hypertens (1993) 0.80
Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother (2007) 0.78
Renin inhibitors in chronic heart failure: the Aliskiren Observation of Heart Failure Treatment study in context. Clin Cardiol (2010) 0.78
Peptide inhibitors of renin in cardiovascular studies. Fed Proc (1983) 0.76
Fluttering thrombus in patent foramen ovale with paradoxical and cerebral embolism. Circulation (2014) 1.97
Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int (2002) 1.61
Can we say that modern radiologic contrast agents are safe in myasthenia gravis? Muscle Nerve (2015) 1.06
Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur J Endocrinol (2004) 1.00
Effects of cigarette smoking on glomerular structure and function in type 2 diabetic patients. J Am Soc Nephrol (2002) 0.87
PC-1 amino acid variant Q121 is associated with a lower glomerular filtration rate in type 2 diabetic patients with abnormal albumin excretion rates. Diabetes Care (2003) 0.83
Clinical and pathological findings of a fatal systemic capillary leak syndrome (Clarkson disease): a case report. Medicine (Baltimore) (2015) 0.78